Download Files:
CJ-13,610
$110 – $1,200
Products Details
Product Description
– CJ-13,610, a nonredox-type 5-LO inhibitor, dose dependently suppresses 5-LO product formation in ionophore A23187-stimulated PMNL in the absence of exogenous AA with an IC50 of about 70 nM[1]. PMNL: polymorphonuclear leukocytes; AA: arachidonic acid
Web ID
– HY-106200
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– C22H23N3O2S
References
– [1]Fischer L, et al. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610. Br J Pharmacol. 2004;142(5):861-868.
CAS Number
– 179420-17-8
Molecular Weight
– 393.50
Compound Purity
– 98.01
SMILES
– NC(C1(C2=CC(SC3=CC=C(N4C(C)=NC=C4)C=C3)=CC=C2)CCOCC1)=O
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology
Solubility
– DMSO : 10 mg/mL (ultrasonic;warming;heat to 60°C)
Target
– Lipoxygenase
Pathway
– Metabolic Enzyme/Protease
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
